These include the substrate-competitive, dual EZH2 and G9A/GLP inhibitor HKMTI-1-005, which was demonstrated to induce differentiation in AML cells and induce responsiveness to all-trans retinoic acid (ATRA) treatment (79). Here, EZH2 is linked to acute myeloid leukemia.